Statistically significant borderline differences in PCSK9 levels was observed between females and males (mean 200.7 ± 220.3 vs 302.0 ± 263.1 ng/mL; P = .071), and between patients with or without history of cancer (mean 165.8 ± 188.1 vs 279.3 ± 257.8 ng/mL; P = .078). The gene discussed is PCSK9; the disease is cancer.